Primary CTO Crossing Device Strategy Provides Superior Midterm Clinical Outcomes Following Peripheral Endovascular Procedures at a Reasonable Additional Cost

Long‐term outcomes after re‐entry device use for recanalization of common iliac artery chronic total occlusions

“…Moreover, because of lower TLR and amputation rates in the crossing device group, the authors concluded that the net cost for an initial CTO crossing device strategy was $423.80 per procedure. Even if XLPAD did not include iliac CTOs, we can speculate that the cost‐benefit results would be similar for these lesions and they may justify the use of RED, despite the higher initial cost .…”